
Walmart Will Require All Locations to Have EPCS in 2020
Walmart announced recently that they will require all of their

Walmart announced recently that they will require all of their

Many in the behavioral health community have found themselves searching

Why We Dedicated Ourselves to Make a Better EHR In

In mid-March, the FDA approved the postpartum depression drug brexanolone,

At a time when most news about the opioid crisis

In the digital era, it is crucial for behavioral

AZZLY joins the Behavioral Health Association of Providers (BHAP) in

If you’re reading this post, you likely already know the

In 2018, five drug distribution executives were summoned to testify

The public will have the opportunity to make comments on
```html
The landscape of mental health and substance abuse treatment is rapidly evolving, with significant developments such as the FDA's recent approval of Zulresso, a drug aimed at treating postpartum depression. While this approval marks a crucial step forward in addressing maternal mental health, concerns about the drug's high cost have sparked debates about accessibility and affordability for those in need. As healthcare providers and patients navigate these challenges, the importance of comprehensive treatment options becomes increasingly clear.
In parallel, the opioid crisis continues to dominate headlines, with a recent CDC study suggesting a potential decline in opioid overdose deaths. However, barriers remain for patients seeking treatment for opioid use disorder, highlighting the need for systemic changes in how we approach addiction and recovery. As advocates push for mandatory counseling and therapeutic interventions in medication-assisted treatment funding, the conversation around effective strategies to combat this public health crisis is more critical than ever.
``````html
The landscape of mental health and substance abuse treatment is rapidly evolving, with significant developments such as the FDA's recent approval of Zulresso, a drug aimed at treating postpartum depression. While this approval marks a crucial step forward in addressing maternal mental health, concerns about the drug's high cost have sparked debates about accessibility and affordability for those in need. As healthcare providers and patients navigate these challenges, the importance of comprehensive treatment options becomes increasingly clear.
In parallel, the opioid crisis continues to dominate headlines, with a recent CDC study suggesting a potential decline in opioid overdose deaths. However, barriers remain for patients seeking treatment for opioid use disorder, highlighting the need for systemic changes in how we approach addiction and recovery. As advocates push for mandatory counseling and therapeutic interventions in medication-assisted treatment funding, the conversation around effective strategies to combat this public health crisis is more critical than ever.
```